Alexey Danilov MD

Summary

• Dr. Danilov earned his medical degree in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, United States. He is a physician-scientist with background in molecular biology and cancer cell signaling and expertise in oncologic drug development. He leads an independent research program in B-cell malignancies which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.
  As a Director of Early Phase Therapeutics Program and a leader of the Lymphoma Center, Dr. Danilov guides an effort in experimental therapeutics at the City of Hope National Medical Center. His group’s pre-clinical focus is on evaluation of novel targets in the ubiquitin-proteasome system and oncogenic role of cyclin-dependent kinase-9. In addition, his group performs correlative science on multiple clinical trials. He received peer-reviewed funding from the National Cancer Institute (R01), Leukemia and Lymphoma Society, American Society of Hematology and Lymphoma Research Foundation, and serves as Co-Chair for Translational Medicine of the Southwest Oncology Group Lymphoma Committee.
  Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his pre-clinical discoveries, he launched multiple early-phase clinical trials with novel agents. As a member of industry and SWOG committees and a leader within the Early Therapeutics Clinical Trials Network, he participates in drug development on a global scale.